Evidence map›Paper›PMID 41385080›Full record

ArticleThe Journal of experimental medicine2026

A circadian checkpoint relocates neutrophils to minimize injury.

Alejandra Aroca-Crevillén, Sandra Martín-Salamanca, Lidiane S Torres, Georgiana Crainiciuc, Jon Sicilia, Eduardo Peñaloza-Martínez, Nicolás Rosillo, Miguel Molina-Moreno, Jose M Adrover, Andrea Rubio-Ponce and 13 more

Abstract read
In one paragraph

Article in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Circadian rhythms and lung cancer biology and immunotherapy: Emerging opportunities and challenges.Chinese medical journal pulmonary and critical care medicine · 2026
    Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Alejandra Aroca-CrevillénSpanish National Centre for Cardiovascular Research Carlos III , Madrid, Spain.ORCID 0000-0002-2481-0863
Sandra Martín-SalamancaSpanish National Centre for Cardiovascular Research Carlos III , Madrid, Spain.ORCID 0009-0002-3624-4149
Lidiane S TorresDepartment of Cell Biology and Ruth L. and David S. Gottesman Institute for Stem Cell Biology and Regenerative Medicine, Albert Einstein College of Medicine, New York, NY, USA.ORCID 0000-0002-4598-1899
Georgiana CrainiciucSpanish National Centre for Cardiovascular Research Carlos III , Madrid, Spain.ORCID 0000-0002-0912-7425
Jon SiciliaSpanish National Centre for Cardiovascular Research Carlos III , Madrid, Spain.ORCID 0000-0002-5073-9132
Eduardo Peñaloza-MartínezCardiology Department. Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0009-0007-1065-9887
Nicolás RosilloCardiology Department. Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0002-4046-8092
Miguel Molina-MorenoVascular Biology and Therapeutics Program and Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-3493-7470
Jose M AdroverCancer Macroenvironment Lab, The Francis Crick Institute , London, UK.ORCID 0000-0002-1395-5477
Andrea Rubio-PonceSpanish National Centre for Cardiovascular Research Carlos III , Madrid, Spain.ORCID 0000-0002-4275-8835
Tommaso VicanoloSpanish National Centre for Cardiovascular Research Carlos III , Madrid, Spain.ORCID 0000-0003-1356-1352
Xiaosong LiuDepartment of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands.ORCID 0009-0006-0620-9341
Kanin WichapongDepartment of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands.ORCID 0000-0002-9678-7084
Vanessa NúñezSpanish National Centre for Cardiovascular Research Carlos III , Madrid, Spain.ORCID 0000-0002-7473-1514
Karl BalabanianUniversité Paris Cité, Institut de Recherche Saint-Louis, INSERM U1342 , Paris, France.ORCID 0000-0002-0534-3198
Françoise BachelerieUniversité Paris-Saclay, Inserm, Inflammation, Microbiome and Immunosurveillance , Orsay, France.ORCID 0000-0002-0399-3277
David SanchoSpanish National Centre for Cardiovascular Research Carlos III , Madrid, Spain.ORCID 0000-0003-2890-3984
María Casanova-AcebesCancer Immunity Laboratory, Spanish National Cancer Centre , Madrid, Spain.ORCID 0000-0002-5790-1163
José T Ortiz-PérezInstitut Clínic Cardiovascular, Hospital Clínic Barcelona and Institut d'investigacions Biomèdiques August Pi i Sunyer, University of Barcelona , Barcelona, Spain.ORCID 0000-0001-8043-6055
María Ángeles MoroSpanish National Centre for Cardiovascular Research Carlos III , Madrid, Spain.ORCID 0000-0003-1010-8237
Héctor BuenoSpanish National Centre for Cardiovascular Research Carlos III , Madrid, Spain.ORCID 0000-0003-0277-7596
Gerry A F NicolaesDepartment of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands.ORCID 0000-0002-2482-0412
Andrés HidalgoSpanish National Centre for Cardiovascular Research Carlos III , Madrid, Spain.ORCID 0000-0001-5513-555X

Funding

In Vivo Sickle Cell Vasoocclusion: Adhesion MechanismsR01HL069438 · NHLBI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI KELLY, LIBUSHA · 2001 to 2024
$9.5M
In vivo function of macrophage in healthy and diseased erythropoiesisR01HL116340 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI FRENETTE, PAUL S · 2012 to 2015
$1.7M
Agence Nationale de la Recherche ANR-17-CE14-0019AstraZenecaBoehringer IngelheimCentro Nacional de Investigaciones CardiovascularesChina Scholarship Council 201606350089European Regional Development FundEuropean Union EU4H-2022-JA-03Fondation pour la Recherche Médicale EQU202203014627Instituto de Salud Carlos III PI21/01572JanssenLa Caixa Foundation HR17_00527La Caixa Foundation LCF/BQ/DR19/11740022La Caixa Foundation LCF/BQ/DR21/11880022Leducq Trans-Atlantic Network of Excellence on Circadian Effects in Stroke TNE-21CVD04Ministerio de Ciencia, Innovación y Universidades PID2022-140616OB-I00Ministerio de Ciencia, Innovación y Universidades PRE2019-089130NHLBI NIH HHS R01 HL069438NHLBI NIH HHS R01 HL116340NIH HHS HL069438NIH HHS HL116340Pro-CNIC FoundationSociedad Española de CardiologíaSpanish State Research Agency CEX2020-001041-SWellcome Trust CC2273
6 · The paper itself

Abstract

Inflammation-driven injury, a significant source of morbidity and mortality worldwide, is largely mediated by the cytotoxic activities of neutrophils, which extend the initial lesion and jeopardize organ function. Intriguingly, inflammatory injury naturally declines at specific times of day, suggesting that circadian mechanisms exist that mitigate the destructive activity of neutrophils and protect the host. Here, we show that the periods of diurnal protection coincide with peaks in plasma CXCL12, a chemokine that inhibits the neutrophil-intrinsic circadian clock by signaling through CXCR4. Genetic deletion of this clock, or a hyperactive form of CXCR4, prevented the diurnal spikes of injury, and treatment with a synthetic CXCR4 agonist conferred protection from myocardial and vascular injury. In tissues, this protection was mediated by repositioning neutrophils in the wound core, which spared neighboring host cells from apoptotic death. Thus, a circadian neutrophil checkpoint protects from exuberant inflammation and can be activated to protect the host.

Indexed as

Circadian ClocksCircadian RhythmNeutrophilsAnimalsApoptosisChemokine CXCL12InflammationMiceMice, Inbred C57BLMice, KnockoutReceptors, CXCR4Signal TransductionChemokine CXCL12Cxcl12 protein, mouseCXCR4 protein, mouseReceptors, CXCR4

Identifiers

PMID41385080
PMCPMC7618653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.